Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions. 

Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.